RxDoctor Payments Data

Andrea Murina, MD

Clinical & Laboratory Dermatological Immunology · New Orleans, LANPI 1295994218

Payments from drug & device makers

$906,168in general payments, 2019–2025

Across 1,005 payments — averaging $901.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$154K
  • UCB, Inc.$145K
  • AbbVie$113K
  • E.r. Squibb & Sons, L.L.C.$108K
  • Amgen$97K
  • Pfizer$59K
  • plus $231K from 26 others

What the payments were for

  • Consulting fees$160,34818%
  • Speaking & faculty fees$648,90873%
  • Travel & lodging$60,3847%
  • Food & beverage$20,9902%
  • Education$2870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical & laboratory dermatological immunology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$44,710
Medicare patients
206
Services billed
1,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$260,786
Enbrel SureclickEtanercept14$197,496
OtezlaApremilast34$169,298
Dupixent SyringeDupilumab36$136,616
Cosentyx Sensoready (2 Pens)Secukinumab15$114,468
SotyktuDeucravacitinib13$87,297
Dupixent PenDupilumab17$65,179
XolairOmalizumab16$39,567
Acitretin25$6,285
Ketoconazole203$2,890
Clobetasol Propionate81$2,453
Dapsone21$1,977
Ivermectin14$1,954
Metronidazole35$1,736
Fluorouracil22$1,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$153,517$260,78615 claims
AmgenOtezla$96,583$169,29834 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$108,356$87,29713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical & laboratory dermatological immunology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other clinical & laboratory dermatological immunology in New Orleans

Where these figures come from

Is this you, or does something look wrong? →